Palivizumab (MEDI 493), a humanized respiratory syncytial virus monoclonal antibody, reduces respiratory syncytial virus (RSV) infection.
| CAS Number | 188039-54-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[3] Georgiana Georgescu, et al. Expert Opin Biol Ther. Palivizumab: where to from here?
| Related RSV Products |
|---|
| 4,5-Di-O-caffeoylquinic acid methyl ester
4,5-O-Dicaffeoyl quinic acid methyl ester (compound 4), a dicaffeoylquinic acid, has potent antiviral activity against respiratory syncytial virus (RSV) with an IC50 of 0.63 μg/mL and a CC50 of 118.68 μg/mL. |
| RSV L-protein-IN-2
RSV L-protein-IN-2 is a noncompetitive RSV polymerase inhibitor (IC50: 4.5 μM). |
| RSV L-protein-IN-4
RSV L-protein-IN-4 is a noncompetitive RSV polymerase inhibitor (IC50: 0.88 μM). |
| RSV L-protein-IN-5
RSV L-protein-IN-5 is a potent inhibitor of Respiratory syncytial virus (RSV) (EC50=0.1 μM). |
| RSV L-protein-IN-1
RSV L-protein-IN-1 is a potent inhibitor of Respiratory syncytial virus (RSV) (EC50=0.021 μM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
